Latest data from clinical trials of Tregalizumab, formerly known as BT-061, provide insight into its potential benefit for treating multiple immune-mediated diseases – particularly, iritis. Phase three trials have indicated a notable lowering in autoimmune reaction, with certain patients achieving periods free from inflammation. Further research